News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genesis Research and Development (AU:GEN) Announces Recruitment Milestone For Phase II Trial Of AVAC(TM) In Childhood Eczema



10/19/2005 5:10:39 PM

Genesis Research and Development Corporation (NZX/ASX:GEN) today announced that a Phase II trial of its childhood eczema therapeutic candidate, AVACâ„¢, has reached the 50 percent enrolment milestone.



comments powered by Disqus
   
Eczema

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES